Kulp W, Hemels M, Greiner W, von der Schulenburg J. Cost-effectiveness analysis of escitalopram in the treatment of Major Depressive Disorder in Germany. In: Value in Health. Value in Health. Vol 8. Blackwell; 2005: A210
The debate on the cost-effectiveness of SSRIs is taking place in the context of a general consensus ...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
OBJECTIVE: To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmac...
Objective: This study assessed the cost-effectiveness of escitalopram for the treatment of depressio...
Background Depressive disorders place a great burden on society and rank as the fourth leading cause...
Claudio Mencacci,1 Guido Di Sciascio,2 Pablo Katz,3 Claudio Ripellino31Ospedale Fatebenefratelli, Mi...
AbstractObjectivesMajor depressive disorder (MDD) is a major public health concern associated with a...
The objective of this study was to assess the cost effectiveness of commonly used antidepressants as...
Introduction: Major depressive disorder (MDD) is a common and disabling condition across the world. ...
Abstract Background Knowledge regarding the relative cost-effectiveness of different antidepressants...
Indexed keywords SciVal Topics Chemicals and CAS Registry Numbers Citations Metrics Abs...
AbstractMethodsWe conducted a multinational pharmacoeconomic evaluation comparing the immediate rele...
The Author(s) 2014. This article is published with open access at Springerlink.com Objective The obj...
BACKGROUND: Generalized anxiety disorder (GAD) is associated with substantial economic burden. OBJEC...
AbstractBackgroundMajor depressive disorder (MDD) is a debilitating psychiatric illness with a high ...
The debate on the cost-effectiveness of SSRIs is taking place in the context of a general consensus ...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
OBJECTIVE: To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmac...
Objective: This study assessed the cost-effectiveness of escitalopram for the treatment of depressio...
Background Depressive disorders place a great burden on society and rank as the fourth leading cause...
Claudio Mencacci,1 Guido Di Sciascio,2 Pablo Katz,3 Claudio Ripellino31Ospedale Fatebenefratelli, Mi...
AbstractObjectivesMajor depressive disorder (MDD) is a major public health concern associated with a...
The objective of this study was to assess the cost effectiveness of commonly used antidepressants as...
Introduction: Major depressive disorder (MDD) is a common and disabling condition across the world. ...
Abstract Background Knowledge regarding the relative cost-effectiveness of different antidepressants...
Indexed keywords SciVal Topics Chemicals and CAS Registry Numbers Citations Metrics Abs...
AbstractMethodsWe conducted a multinational pharmacoeconomic evaluation comparing the immediate rele...
The Author(s) 2014. This article is published with open access at Springerlink.com Objective The obj...
BACKGROUND: Generalized anxiety disorder (GAD) is associated with substantial economic burden. OBJEC...
AbstractBackgroundMajor depressive disorder (MDD) is a debilitating psychiatric illness with a high ...
The debate on the cost-effectiveness of SSRIs is taking place in the context of a general consensus ...
To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmacological fi...
OBJECTIVE: To determine effectiveness and cost-effectiveness over a one-year time horizon of pharmac...
DOI
Add to ORKG